NO995823L - Terapeutisk middel for ereksjonsdysfunksjon - Google Patents

Terapeutisk middel for ereksjonsdysfunksjon

Info

Publication number
NO995823L
NO995823L NO995823A NO995823A NO995823L NO 995823 L NO995823 L NO 995823L NO 995823 A NO995823 A NO 995823A NO 995823 A NO995823 A NO 995823A NO 995823 L NO995823 L NO 995823L
Authority
NO
Norway
Prior art keywords
therapeutic agent
erectile dysfunction
erectile
dysfunction
therapeutic
Prior art date
Application number
NO995823A
Other languages
English (en)
Norwegian (no)
Other versions
NO995823D0 (no
Inventor
Tatsuto Notsu
Nobuo Ohzawa
Yasuhiro Nakai
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of NO995823D0 publication Critical patent/NO995823D0/no
Publication of NO995823L publication Critical patent/NO995823L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO995823A 1997-05-29 1999-11-26 Terapeutisk middel for ereksjonsdysfunksjon NO995823L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4029797P 1997-05-29 1997-05-29
JP34413497 1997-11-29
PCT/JP1998/002378 WO1998053819A1 (fr) 1997-05-29 1998-05-29 Agent therapeutique destine a traiter l'anerection

Publications (2)

Publication Number Publication Date
NO995823D0 NO995823D0 (no) 1999-11-26
NO995823L true NO995823L (no) 2000-01-28

Family

ID=26577702

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995823A NO995823L (no) 1997-05-29 1999-11-26 Terapeutisk middel for ereksjonsdysfunksjon

Country Status (9)

Country Link
EP (1) EP0992240A4 (de)
KR (1) KR20010012995A (de)
CN (1) CN1309561A (de)
AU (1) AU739417B2 (de)
BR (1) BR9809508A (de)
CA (1) CA2291256A1 (de)
IL (1) IL132993A0 (de)
NO (1) NO995823L (de)
WO (1) WO1998053819A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
AU1414200A (en) * 1998-12-02 2000-06-19 Mochida Pharmaceutical Co., Ltd. Preparations for intraurethral administration
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
WO2000054777A1 (en) * 1999-03-16 2000-09-21 Pentech Pharmaceuticals, Inc. Controlled release of sildenafil delivered by sublingual or buccal administration
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CA2391968A1 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
AU2001255849B8 (en) 2000-04-19 2006-04-27 Lilly Icos, Llc. PDE-V inhibitors for treatment of Parkinson's Disease
AU2001273545A1 (en) * 2000-07-19 2002-01-30 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
EP1404336A1 (de) * 2001-06-14 2004-04-07 Sampad Bhattacharya Zusammensetzungen enthaltend cgmp-pde5-hemmar zur transdermalen verabreichung zur erektilgewebe des penises
WO2004011029A2 (en) 2002-07-26 2004-02-05 Adams Kenneth W Pharmaceutical compositions for penis enlargement
US7662831B2 (en) 2006-07-27 2010-02-16 Wyeth Llc Tetracyclic indoles as potassium channel modulators
CN101429166B (zh) * 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
EP2526926A1 (de) * 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nanopolymerpartikel mit Wirkstoffen für die pulmonale Applikation
ES2692663T3 (es) * 2011-12-26 2018-12-04 Tritech Biopharmaceuticals Co. Ltd. Método y composición farmacéutica mejorada para mejorar la entrega transdérmica del inhibidor PDE-5
CA2994709A1 (en) * 2015-08-03 2017-02-09 Synergistic Therapeutics, Llc Sexual dysfunction therapeutic gel
JP6865933B2 (ja) 2018-02-23 2021-04-28 株式会社Ｍｅｉｓ Ｔｅｃｈｎｏｌｏｇｙ 勃起不全治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
DE69514794T2 (de) * 1994-04-22 2000-07-27 Pentech Pharmaceuticals Inc Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
WO1997045427A1 (fr) * 1996-05-31 1997-12-04 Mochida Pharmaceutical Co., Ltd. DERIVES DE PYRIDOCARBAZOLE AYANT UN EFFET INHIBITEUR DE cGMP-PDE
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process

Also Published As

Publication number Publication date
AU739417B2 (en) 2001-10-11
WO1998053819A1 (fr) 1998-12-03
CN1309561A (zh) 2001-08-22
AU7454898A (en) 1998-12-30
NO995823D0 (no) 1999-11-26
CA2291256A1 (en) 1998-12-03
EP0992240A4 (de) 2003-04-16
KR20010012995A (ko) 2001-02-26
IL132993A0 (en) 2001-03-19
BR9809508A (pt) 2000-06-20
EP0992240A1 (de) 2000-04-12

Similar Documents

Publication Publication Date Title
NO995823D0 (no) Terapeutisk middel for ereksjonsdysfunksjon
ID22834A (id) Pirazolopimidinona untuk kelainan seksual
IS2494B (is) Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni
NO992806D0 (no) Terapeutiske midler
GB9905010D0 (en) Therapeutic agents
NO20022692L (no) Terapeutiske midler
NO980546D0 (no) Farmasöytiske midler
GB9904786D0 (en) Therapeutic agents
GB9929685D0 (en) Therapeutic agents
NO20005179D0 (no) Medikament behandling
NO990805L (no) Middel for ereksjonssvikt omfattende kondenserte pyridazinforbindelser
GB9911881D0 (en) Therapeutic agents
GB9921351D0 (en) Therapeutic agents
NO20000969L (no) Ftalazinderivater og midler for erektil dysfunksjon
NO20001196D0 (no) Nootropisk middel
GB9929569D0 (en) Therapeutic agents
GB9903476D0 (en) Therapeutic agents
GB9914744D0 (en) Therapeutic agents
NO20012226L (no) Terapeutiske midler for medikamentavhengighet
IS5814A (is) Ný lyfjafræðileg notkun á NOS lötum
NO20016301D0 (no) Terapeutiske midler
GB9914745D0 (en) Therapeutic agents
GB9902881D0 (en) Therapeutic agents
GB9914743D0 (en) Therapeutic agents
ES1041026Y (es) Vibrador terapeutico.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application